- Company Receives Allowance of Patent Claims in the U.S. and in India -
- InNexus Biotechnology CEO Highlighted in Nature Biotechnology -
InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com),
a drug development company commercializing the next generation of
monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM))
technology, announces that it has received a notice of allowance on
patent claims in the United States (Serial No. 11/119,404) and a patent grant in India (National Phase Application No. 2424/CHENP/2005) further expanding its protection of InNexus' DXL(TM) technology.
Speaking on today's announcement, InNexus Chairman and CEO,
Jeff Morhet
said, "DXL(TM) antibodies that penetrate directly into cells, is an
exciting achievement for InNexus and our industry. As we've continued
to expand our patent portfolio and discover new technologies to develop
products, the team has aggressively pursued patent protection for our
novel inventions. Patents are the currency of our industry and a driver
for enhanced value for our shareholders and potential use of these cell
penetrating DXL(TM) antibodies represents another frontier for the use
of antibodies for therapeutic and diagnostic applications."
•
del.icio.us
digg
facebook
E-mail this article to a friend (requires login).